EGFR L858R and T790M coexistence before first line therapy in pulmonary adenocarcinoma - case report

被引：0
|
作者：
Sousa, V. [1 ]
Alarcao, A. [1 ]
Ladeirinha, A. F. [1 ]
Reis Silva, M. [1 ]
Balseiro, S. [1 ]
Ferreira, T. [1 ]
d'Aguiar, M. J. [1 ]
Figueiredo, A. [1 ]
Barata, F. [1 ]
Carvalho, L. [1 ]
机构：
[1] UC, IAP, Fac Med, Coimbra, Portugal
来源：
VIRCHOWS ARCHIV | 2018年 / 473卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-21-02
引用
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [1] Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
    Saldana-Rivera, Lucia
    Bello, Martiniano
    Mendez-Luna, David
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (17): : 4671 - 4684
  • [2] Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis
    Bello, Martiniano
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 118 : 1948 - 1962
  • [3] L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report
    Xiang, Xianhong
    Yu, Jianxing
    Lai, Yingrong
    He, Weiling
    Li, Shuhua
    Wang, Liantang
    Ke, Zunfu
    ONCOLOGY LETTERS, 2015, 10 (03) : 1293 - 1296
  • [4] Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR
    Todsaporn, Duangjai
    Zubenko, Alexander
    Kartsev, Victor G.
    Mahalapbutr, Panupong
    Geronikaki, Athina
    Sirakanyan, Samvel N.
    Divaeva, Lyudmila N.
    Chekrisheva, Victoria
    Yildiz, Ilkay
    Choowongkomon, Kiattawee
    Rungrotmongkol, Thanyada
    JOURNAL OF PHYSICAL CHEMISTRY B, 2024, 128 (50): : 12389 - 12402
  • [5] Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
    Hoogenboom, Niels
    Demont, Dennis
    de Zwart, Edwin
    Verkaik, Saskia
    Emmelot, Maaike
    van de Kar, Bas
    Kaptein, Allard
    Barf, Tjeerd
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 52
  • [6] Detection of EGFR Mutations T790M and L858R for Therapeutic Guidance of NSCLC
    Rana, M.
    Asil, S. M.
    Boutin, C.
    Kachwala, M. J.
    Espejo, J.
    Argun, A. A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S496 - S496
  • [7] Case report of three EGFR TKI naive lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology
    Sakashita, Shingo
    Shiba-Ishii, Aya
    Murata, Yoshihiko
    Sekimoto, Ryutaro
    Minami, Yuko
    Sato, Yukio
    Noguchi, Masayuki
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (08) : 1224 - 1230
  • [8] QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
    Fatima, Shehnaz
    Pal, Divyani
    Agarwal, Subhash Mohan
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 94 (01) : 1306 - 1315
  • [9] Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
    Kim, Ji Yeon
    Lee, Woo Jeong
    Park, Ha Young
    Kim, Ahrong
    Shin, Dong Hoon
    Lee, Chang Hun
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2018, 52 (05) : 275 - 282
  • [10] A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
    Fawwaz, Muammar
    Mishiro, Kenji
    Nishii, Ryuichi
    Makino, Akira
    Kiyono, Yasushi
    Shiba, Kazuhiro
    Kinuya, Seigo
    Ogawa, Kazuma
    PHARMACEUTICALS, 2021, 14 (03)
12345